Global Drug Discovery

Drug Discovery Comprehensive Study by Type (Small Molecule Drug, Biologics Drug), Technology (High Throughput Screening, Pharmacogenomics, Combinatorial Chemistry, Nanotechnology, Other Technologies), Stages (Early Drug Discovery, Pre-Clinical Phase, Clinical Phases, Regulatory Approval), End User (Pharmaceutical Companies, Contract Research Organizations (CROs), Others), Therapeutic Area (Oncology, Neurological Diseases, Infectious Diseases, Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Rare Diseases, Others) Players and Region - Global Market Outlook to 2028

Drug Discovery Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 9.81%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Drug Discovery Market Scope
Drug discovery refers to the clinical process of new drug development. Drug discovery market has high growth prospects owing to growth in the clinical research industry. Further, the increasing number of patients with chronic diseases such as cardiovascular disease, cancer, diabetics, and others driving the demand for novel drugs. In addition, growing healthcare infrastructure and technological advancement in the drug discovery technologies expected to drive the demand for the drug discovery market over the forecasted period.

According to AMA, the Global Drug Discovery market is expected to see growth rate of 9.81%

Market players are focusing on partnership, collaborations, and new product launch in order to increase their offerings in the drug discovery market. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Drug Discovery market throughout the predicted period.

Pfizer Inc. (United States), GlaxoSmithKline PLC (United Kingdom), Abbott Laboratories (United States), Merck & Co. Inc. (United States), Agilent Technologies Inc. (United States), Eli Lilly and Company (United States), Roche Holding AG (Switzerland), Bayer AG (Germany), Caliper Life Sciences (United States), AstraZeneca PLC (United Kingdom), Shimadzu Corp. (Japan), Evotec (Germany), Thermo Fisher Scientific Inc. (United States), Biogen (United States), Bristol-Myers Squibb Company (United States), IQVIA Inc (United States), Piramal Pharma Solutions (India), Domainex (united Kingdom), Takeda Pharmaceutical Company Limited (Japan), Jubilant Pharmova Limited (India) and Viva Biotech (China) are some of the key players that are part of study coverage.

Segmentation Overview
The study have segmented the market of Global Drug Discovery market by Type (Small Molecule Drug and Biologics Drug) and Region with country level break-up.

On the basis of geography, the market of Drug Discovery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Growing Clinical Research Industry and Technological Advancement in the Drug Discovery Techniques

Market Growth Drivers:
Rising Demand for the Biological Drugs and Increasing Prevalence of Chronic Diseases

Challenges:
Lack of Skilled Professionals to Adopt New Drug Discovery Technologies and Lack of Advanced Healthcare Facilities in the Low and Middle Income Group Countries

Restraints:
Stringent Government Regulations Regarding Medicine and Drugs and High Capital Investment for the Drug Discovery Settings

Opportunities:
Rising Demand of Small Molecule Drugs for Treating Chronic Diseases and Increasing Healthcare Expenditure in the Developing Economies


“The FDA’s Center for Drug Evaluation and Research, or CDER, is the specific body within the FDA that is involved with reviewing the new drug development process. The CDER has in-depth understanding of the science used to create new products, testing processes and manufacturing procedures, and the diseases and conditions that are sought to be treated by new products. The CDER provides the scientific and regulatory advice needed to bring new products to market.”

Key Target Audience
Healthcare Institutes, Potential Investors, Associations, Organizations, Forums, and Alliances, Government Bodies and Departments, Research Institutes, Business Consulting Firms and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Type
  • Small Molecule Drug
  • Biologics Drug
By Technology
  • High Throughput Screening
  • Pharmacogenomics
  • Combinatorial Chemistry
  • Nanotechnology
  • Other Technologies

By Stages
  • Early Drug Discovery
  • Pre-Clinical Phase
  • Clinical Phases
  • Regulatory Approval

By End User
  • Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Others

By Therapeutic Area
  • Oncology
  • Neurological Diseases
  • Infectious Diseases
  • Immune System Diseases
  • Digestive System Diseases
  • Cardiovascular Diseases
  • Rare Diseases
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for the Biological Drugs
      • 3.2.2. Increasing Prevalence of Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professionals to Adopt New Drug Discovery Technologies
      • 3.3.2. Lack of Advanced Healthcare Facilities in the Low and Middle Income Group Countries
    • 3.4. Market Trends
      • 3.4.1. Growing Clinical Research Industry
      • 3.4.2. Technological Advancement in the Drug Discovery Techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug Discovery, by Type, Technology, Stages, End User, Therapeutic Area and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Drug Discovery (Value)
      • 5.2.1. Global Drug Discovery by: Type (Value)
        • 5.2.1.1. Small Molecule Drug
        • 5.2.1.2. Biologics Drug
      • 5.2.2. Global Drug Discovery by: Technology (Value)
        • 5.2.2.1. High Throughput Screening
        • 5.2.2.2. Pharmacogenomics
        • 5.2.2.3. Combinatorial Chemistry
        • 5.2.2.4. Nanotechnology
        • 5.2.2.5. Other Technologies
      • 5.2.3. Global Drug Discovery by: Stages (Value)
        • 5.2.3.1. Early Drug Discovery
        • 5.2.3.2. Pre-Clinical Phase
        • 5.2.3.3. Clinical Phases
        • 5.2.3.4. Regulatory Approval
      • 5.2.4. Global Drug Discovery by: End User (Value)
        • 5.2.4.1. Pharmaceutical Companies
        • 5.2.4.2. Contract Research Organizations (CROs)
        • 5.2.4.3. Others
      • 5.2.5. Global Drug Discovery by: Therapeutic Area (Value)
        • 5.2.5.1. Oncology
        • 5.2.5.2. Neurological Diseases
        • 5.2.5.3. Infectious Diseases
        • 5.2.5.4. Immune System Diseases
        • 5.2.5.5. Digestive System Diseases
        • 5.2.5.6. Cardiovascular Diseases
        • 5.2.5.7. Rare Diseases
        • 5.2.5.8. Others
      • 5.2.6. Global Drug Discovery Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Drug Discovery (Price)
      • 5.3.1. Global Drug Discovery by: Type (Price)
  • 6. Drug Discovery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Agilent Technologies Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer AG (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Caliper Life Sciences (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca PLC (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Shimadzu Corp. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Evotec (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Thermo Fisher Scientific Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Biogen (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Bristol-Myers Squibb Company (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. IQVIA Inc (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Piramal Pharma Solutions (India)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Domainex (united Kingdom)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
      • 6.4.20. Jubilant Pharmova Limited (India)
        • 6.4.20.1. Business Overview
        • 6.4.20.2. Products/Services Offerings
        • 6.4.20.3. Financial Analysis
        • 6.4.20.4. SWOT Analysis
      • 6.4.21. Viva Biotech (China)
        • 6.4.21.1. Business Overview
        • 6.4.21.2. Products/Services Offerings
        • 6.4.21.3. Financial Analysis
        • 6.4.21.4. SWOT Analysis
  • 7. Global Drug Discovery Sale, by Type, Technology, Stages, End User, Therapeutic Area and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Drug Discovery (Value)
      • 7.2.1. Global Drug Discovery by: Type (Value)
        • 7.2.1.1. Small Molecule Drug
        • 7.2.1.2. Biologics Drug
      • 7.2.2. Global Drug Discovery by: Technology (Value)
        • 7.2.2.1. High Throughput Screening
        • 7.2.2.2. Pharmacogenomics
        • 7.2.2.3. Combinatorial Chemistry
        • 7.2.2.4. Nanotechnology
        • 7.2.2.5. Other Technologies
      • 7.2.3. Global Drug Discovery by: Stages (Value)
        • 7.2.3.1. Early Drug Discovery
        • 7.2.3.2. Pre-Clinical Phase
        • 7.2.3.3. Clinical Phases
        • 7.2.3.4. Regulatory Approval
      • 7.2.4. Global Drug Discovery by: End User (Value)
        • 7.2.4.1. Pharmaceutical Companies
        • 7.2.4.2. Contract Research Organizations (CROs)
        • 7.2.4.3. Others
      • 7.2.5. Global Drug Discovery by: Therapeutic Area (Value)
        • 7.2.5.1. Oncology
        • 7.2.5.2. Neurological Diseases
        • 7.2.5.3. Infectious Diseases
        • 7.2.5.4. Immune System Diseases
        • 7.2.5.5. Digestive System Diseases
        • 7.2.5.6. Cardiovascular Diseases
        • 7.2.5.7. Rare Diseases
        • 7.2.5.8. Others
      • 7.2.6. Global Drug Discovery Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Drug Discovery (Price)
      • 7.3.1. Global Drug Discovery by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug Discovery: by Type(USD Million)
  • Table 2. Drug Discovery Small Molecule Drug , by Region USD Million (2017-2022)
  • Table 3. Drug Discovery Biologics Drug , by Region USD Million (2017-2022)
  • Table 4. Drug Discovery: by Technology(USD Million)
  • Table 5. Drug Discovery High Throughput Screening , by Region USD Million (2017-2022)
  • Table 6. Drug Discovery Pharmacogenomics , by Region USD Million (2017-2022)
  • Table 7. Drug Discovery Combinatorial Chemistry , by Region USD Million (2017-2022)
  • Table 8. Drug Discovery Nanotechnology , by Region USD Million (2017-2022)
  • Table 9. Drug Discovery Other Technologies , by Region USD Million (2017-2022)
  • Table 10. Drug Discovery: by Stages(USD Million)
  • Table 11. Drug Discovery Early Drug Discovery , by Region USD Million (2017-2022)
  • Table 12. Drug Discovery Pre-Clinical Phase , by Region USD Million (2017-2022)
  • Table 13. Drug Discovery Clinical Phases , by Region USD Million (2017-2022)
  • Table 14. Drug Discovery Regulatory Approval , by Region USD Million (2017-2022)
  • Table 15. Drug Discovery: by End User(USD Million)
  • Table 16. Drug Discovery Pharmaceutical Companies , by Region USD Million (2017-2022)
  • Table 17. Drug Discovery Contract Research Organizations (CROs) , by Region USD Million (2017-2022)
  • Table 18. Drug Discovery Others , by Region USD Million (2017-2022)
  • Table 19. Drug Discovery: by Therapeutic Area(USD Million)
  • Table 20. Drug Discovery Oncology , by Region USD Million (2017-2022)
  • Table 21. Drug Discovery Neurological Diseases , by Region USD Million (2017-2022)
  • Table 22. Drug Discovery Infectious Diseases , by Region USD Million (2017-2022)
  • Table 23. Drug Discovery Immune System Diseases , by Region USD Million (2017-2022)
  • Table 24. Drug Discovery Digestive System Diseases , by Region USD Million (2017-2022)
  • Table 25. Drug Discovery Cardiovascular Diseases , by Region USD Million (2017-2022)
  • Table 26. Drug Discovery Rare Diseases , by Region USD Million (2017-2022)
  • Table 27. Drug Discovery Others , by Region USD Million (2017-2022)
  • Table 28. South America Drug Discovery, by Country USD Million (2017-2022)
  • Table 29. South America Drug Discovery, by Type USD Million (2017-2022)
  • Table 30. South America Drug Discovery, by Technology USD Million (2017-2022)
  • Table 31. South America Drug Discovery, by Stages USD Million (2017-2022)
  • Table 32. South America Drug Discovery, by End User USD Million (2017-2022)
  • Table 33. South America Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 34. Brazil Drug Discovery, by Type USD Million (2017-2022)
  • Table 35. Brazil Drug Discovery, by Technology USD Million (2017-2022)
  • Table 36. Brazil Drug Discovery, by Stages USD Million (2017-2022)
  • Table 37. Brazil Drug Discovery, by End User USD Million (2017-2022)
  • Table 38. Brazil Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 39. Argentina Drug Discovery, by Type USD Million (2017-2022)
  • Table 40. Argentina Drug Discovery, by Technology USD Million (2017-2022)
  • Table 41. Argentina Drug Discovery, by Stages USD Million (2017-2022)
  • Table 42. Argentina Drug Discovery, by End User USD Million (2017-2022)
  • Table 43. Argentina Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 44. Rest of South America Drug Discovery, by Type USD Million (2017-2022)
  • Table 45. Rest of South America Drug Discovery, by Technology USD Million (2017-2022)
  • Table 46. Rest of South America Drug Discovery, by Stages USD Million (2017-2022)
  • Table 47. Rest of South America Drug Discovery, by End User USD Million (2017-2022)
  • Table 48. Rest of South America Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 49. Asia Pacific Drug Discovery, by Country USD Million (2017-2022)
  • Table 50. Asia Pacific Drug Discovery, by Type USD Million (2017-2022)
  • Table 51. Asia Pacific Drug Discovery, by Technology USD Million (2017-2022)
  • Table 52. Asia Pacific Drug Discovery, by Stages USD Million (2017-2022)
  • Table 53. Asia Pacific Drug Discovery, by End User USD Million (2017-2022)
  • Table 54. Asia Pacific Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 55. China Drug Discovery, by Type USD Million (2017-2022)
  • Table 56. China Drug Discovery, by Technology USD Million (2017-2022)
  • Table 57. China Drug Discovery, by Stages USD Million (2017-2022)
  • Table 58. China Drug Discovery, by End User USD Million (2017-2022)
  • Table 59. China Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 60. Japan Drug Discovery, by Type USD Million (2017-2022)
  • Table 61. Japan Drug Discovery, by Technology USD Million (2017-2022)
  • Table 62. Japan Drug Discovery, by Stages USD Million (2017-2022)
  • Table 63. Japan Drug Discovery, by End User USD Million (2017-2022)
  • Table 64. Japan Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 65. India Drug Discovery, by Type USD Million (2017-2022)
  • Table 66. India Drug Discovery, by Technology USD Million (2017-2022)
  • Table 67. India Drug Discovery, by Stages USD Million (2017-2022)
  • Table 68. India Drug Discovery, by End User USD Million (2017-2022)
  • Table 69. India Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 70. South Korea Drug Discovery, by Type USD Million (2017-2022)
  • Table 71. South Korea Drug Discovery, by Technology USD Million (2017-2022)
  • Table 72. South Korea Drug Discovery, by Stages USD Million (2017-2022)
  • Table 73. South Korea Drug Discovery, by End User USD Million (2017-2022)
  • Table 74. South Korea Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 75. Taiwan Drug Discovery, by Type USD Million (2017-2022)
  • Table 76. Taiwan Drug Discovery, by Technology USD Million (2017-2022)
  • Table 77. Taiwan Drug Discovery, by Stages USD Million (2017-2022)
  • Table 78. Taiwan Drug Discovery, by End User USD Million (2017-2022)
  • Table 79. Taiwan Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 80. Australia Drug Discovery, by Type USD Million (2017-2022)
  • Table 81. Australia Drug Discovery, by Technology USD Million (2017-2022)
  • Table 82. Australia Drug Discovery, by Stages USD Million (2017-2022)
  • Table 83. Australia Drug Discovery, by End User USD Million (2017-2022)
  • Table 84. Australia Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 85. Rest of Asia-Pacific Drug Discovery, by Type USD Million (2017-2022)
  • Table 86. Rest of Asia-Pacific Drug Discovery, by Technology USD Million (2017-2022)
  • Table 87. Rest of Asia-Pacific Drug Discovery, by Stages USD Million (2017-2022)
  • Table 88. Rest of Asia-Pacific Drug Discovery, by End User USD Million (2017-2022)
  • Table 89. Rest of Asia-Pacific Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 90. Europe Drug Discovery, by Country USD Million (2017-2022)
  • Table 91. Europe Drug Discovery, by Type USD Million (2017-2022)
  • Table 92. Europe Drug Discovery, by Technology USD Million (2017-2022)
  • Table 93. Europe Drug Discovery, by Stages USD Million (2017-2022)
  • Table 94. Europe Drug Discovery, by End User USD Million (2017-2022)
  • Table 95. Europe Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 96. Germany Drug Discovery, by Type USD Million (2017-2022)
  • Table 97. Germany Drug Discovery, by Technology USD Million (2017-2022)
  • Table 98. Germany Drug Discovery, by Stages USD Million (2017-2022)
  • Table 99. Germany Drug Discovery, by End User USD Million (2017-2022)
  • Table 100. Germany Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 101. France Drug Discovery, by Type USD Million (2017-2022)
  • Table 102. France Drug Discovery, by Technology USD Million (2017-2022)
  • Table 103. France Drug Discovery, by Stages USD Million (2017-2022)
  • Table 104. France Drug Discovery, by End User USD Million (2017-2022)
  • Table 105. France Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 106. Italy Drug Discovery, by Type USD Million (2017-2022)
  • Table 107. Italy Drug Discovery, by Technology USD Million (2017-2022)
  • Table 108. Italy Drug Discovery, by Stages USD Million (2017-2022)
  • Table 109. Italy Drug Discovery, by End User USD Million (2017-2022)
  • Table 110. Italy Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 111. United Kingdom Drug Discovery, by Type USD Million (2017-2022)
  • Table 112. United Kingdom Drug Discovery, by Technology USD Million (2017-2022)
  • Table 113. United Kingdom Drug Discovery, by Stages USD Million (2017-2022)
  • Table 114. United Kingdom Drug Discovery, by End User USD Million (2017-2022)
  • Table 115. United Kingdom Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 116. Netherlands Drug Discovery, by Type USD Million (2017-2022)
  • Table 117. Netherlands Drug Discovery, by Technology USD Million (2017-2022)
  • Table 118. Netherlands Drug Discovery, by Stages USD Million (2017-2022)
  • Table 119. Netherlands Drug Discovery, by End User USD Million (2017-2022)
  • Table 120. Netherlands Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 121. Rest of Europe Drug Discovery, by Type USD Million (2017-2022)
  • Table 122. Rest of Europe Drug Discovery, by Technology USD Million (2017-2022)
  • Table 123. Rest of Europe Drug Discovery, by Stages USD Million (2017-2022)
  • Table 124. Rest of Europe Drug Discovery, by End User USD Million (2017-2022)
  • Table 125. Rest of Europe Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 126. MEA Drug Discovery, by Country USD Million (2017-2022)
  • Table 127. MEA Drug Discovery, by Type USD Million (2017-2022)
  • Table 128. MEA Drug Discovery, by Technology USD Million (2017-2022)
  • Table 129. MEA Drug Discovery, by Stages USD Million (2017-2022)
  • Table 130. MEA Drug Discovery, by End User USD Million (2017-2022)
  • Table 131. MEA Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 132. Middle East Drug Discovery, by Type USD Million (2017-2022)
  • Table 133. Middle East Drug Discovery, by Technology USD Million (2017-2022)
  • Table 134. Middle East Drug Discovery, by Stages USD Million (2017-2022)
  • Table 135. Middle East Drug Discovery, by End User USD Million (2017-2022)
  • Table 136. Middle East Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 137. Africa Drug Discovery, by Type USD Million (2017-2022)
  • Table 138. Africa Drug Discovery, by Technology USD Million (2017-2022)
  • Table 139. Africa Drug Discovery, by Stages USD Million (2017-2022)
  • Table 140. Africa Drug Discovery, by End User USD Million (2017-2022)
  • Table 141. Africa Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 142. North America Drug Discovery, by Country USD Million (2017-2022)
  • Table 143. North America Drug Discovery, by Type USD Million (2017-2022)
  • Table 144. North America Drug Discovery, by Technology USD Million (2017-2022)
  • Table 145. North America Drug Discovery, by Stages USD Million (2017-2022)
  • Table 146. North America Drug Discovery, by End User USD Million (2017-2022)
  • Table 147. North America Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 148. United States Drug Discovery, by Type USD Million (2017-2022)
  • Table 149. United States Drug Discovery, by Technology USD Million (2017-2022)
  • Table 150. United States Drug Discovery, by Stages USD Million (2017-2022)
  • Table 151. United States Drug Discovery, by End User USD Million (2017-2022)
  • Table 152. United States Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 153. Canada Drug Discovery, by Type USD Million (2017-2022)
  • Table 154. Canada Drug Discovery, by Technology USD Million (2017-2022)
  • Table 155. Canada Drug Discovery, by Stages USD Million (2017-2022)
  • Table 156. Canada Drug Discovery, by End User USD Million (2017-2022)
  • Table 157. Canada Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 158. Mexico Drug Discovery, by Type USD Million (2017-2022)
  • Table 159. Mexico Drug Discovery, by Technology USD Million (2017-2022)
  • Table 160. Mexico Drug Discovery, by Stages USD Million (2017-2022)
  • Table 161. Mexico Drug Discovery, by End User USD Million (2017-2022)
  • Table 162. Mexico Drug Discovery, by Therapeutic Area USD Million (2017-2022)
  • Table 163. Drug Discovery: by Type(USD/Units)
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Drug Discovery: by Type(USD Million)
  • Table 186. Drug Discovery Small Molecule Drug , by Region USD Million (2023-2028)
  • Table 187. Drug Discovery Biologics Drug , by Region USD Million (2023-2028)
  • Table 188. Drug Discovery: by Technology(USD Million)
  • Table 189. Drug Discovery High Throughput Screening , by Region USD Million (2023-2028)
  • Table 190. Drug Discovery Pharmacogenomics , by Region USD Million (2023-2028)
  • Table 191. Drug Discovery Combinatorial Chemistry , by Region USD Million (2023-2028)
  • Table 192. Drug Discovery Nanotechnology , by Region USD Million (2023-2028)
  • Table 193. Drug Discovery Other Technologies , by Region USD Million (2023-2028)
  • Table 194. Drug Discovery: by Stages(USD Million)
  • Table 195. Drug Discovery Early Drug Discovery , by Region USD Million (2023-2028)
  • Table 196. Drug Discovery Pre-Clinical Phase , by Region USD Million (2023-2028)
  • Table 197. Drug Discovery Clinical Phases , by Region USD Million (2023-2028)
  • Table 198. Drug Discovery Regulatory Approval , by Region USD Million (2023-2028)
  • Table 199. Drug Discovery: by End User(USD Million)
  • Table 200. Drug Discovery Pharmaceutical Companies , by Region USD Million (2023-2028)
  • Table 201. Drug Discovery Contract Research Organizations (CROs) , by Region USD Million (2023-2028)
  • Table 202. Drug Discovery Others , by Region USD Million (2023-2028)
  • Table 203. Drug Discovery: by Therapeutic Area(USD Million)
  • Table 204. Drug Discovery Oncology , by Region USD Million (2023-2028)
  • Table 205. Drug Discovery Neurological Diseases , by Region USD Million (2023-2028)
  • Table 206. Drug Discovery Infectious Diseases , by Region USD Million (2023-2028)
  • Table 207. Drug Discovery Immune System Diseases , by Region USD Million (2023-2028)
  • Table 208. Drug Discovery Digestive System Diseases , by Region USD Million (2023-2028)
  • Table 209. Drug Discovery Cardiovascular Diseases , by Region USD Million (2023-2028)
  • Table 210. Drug Discovery Rare Diseases , by Region USD Million (2023-2028)
  • Table 211. Drug Discovery Others , by Region USD Million (2023-2028)
  • Table 212. South America Drug Discovery, by Country USD Million (2023-2028)
  • Table 213. South America Drug Discovery, by Type USD Million (2023-2028)
  • Table 214. South America Drug Discovery, by Technology USD Million (2023-2028)
  • Table 215. South America Drug Discovery, by Stages USD Million (2023-2028)
  • Table 216. South America Drug Discovery, by End User USD Million (2023-2028)
  • Table 217. South America Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 218. Brazil Drug Discovery, by Type USD Million (2023-2028)
  • Table 219. Brazil Drug Discovery, by Technology USD Million (2023-2028)
  • Table 220. Brazil Drug Discovery, by Stages USD Million (2023-2028)
  • Table 221. Brazil Drug Discovery, by End User USD Million (2023-2028)
  • Table 222. Brazil Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 223. Argentina Drug Discovery, by Type USD Million (2023-2028)
  • Table 224. Argentina Drug Discovery, by Technology USD Million (2023-2028)
  • Table 225. Argentina Drug Discovery, by Stages USD Million (2023-2028)
  • Table 226. Argentina Drug Discovery, by End User USD Million (2023-2028)
  • Table 227. Argentina Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 228. Rest of South America Drug Discovery, by Type USD Million (2023-2028)
  • Table 229. Rest of South America Drug Discovery, by Technology USD Million (2023-2028)
  • Table 230. Rest of South America Drug Discovery, by Stages USD Million (2023-2028)
  • Table 231. Rest of South America Drug Discovery, by End User USD Million (2023-2028)
  • Table 232. Rest of South America Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 233. Asia Pacific Drug Discovery, by Country USD Million (2023-2028)
  • Table 234. Asia Pacific Drug Discovery, by Type USD Million (2023-2028)
  • Table 235. Asia Pacific Drug Discovery, by Technology USD Million (2023-2028)
  • Table 236. Asia Pacific Drug Discovery, by Stages USD Million (2023-2028)
  • Table 237. Asia Pacific Drug Discovery, by End User USD Million (2023-2028)
  • Table 238. Asia Pacific Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 239. China Drug Discovery, by Type USD Million (2023-2028)
  • Table 240. China Drug Discovery, by Technology USD Million (2023-2028)
  • Table 241. China Drug Discovery, by Stages USD Million (2023-2028)
  • Table 242. China Drug Discovery, by End User USD Million (2023-2028)
  • Table 243. China Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 244. Japan Drug Discovery, by Type USD Million (2023-2028)
  • Table 245. Japan Drug Discovery, by Technology USD Million (2023-2028)
  • Table 246. Japan Drug Discovery, by Stages USD Million (2023-2028)
  • Table 247. Japan Drug Discovery, by End User USD Million (2023-2028)
  • Table 248. Japan Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 249. India Drug Discovery, by Type USD Million (2023-2028)
  • Table 250. India Drug Discovery, by Technology USD Million (2023-2028)
  • Table 251. India Drug Discovery, by Stages USD Million (2023-2028)
  • Table 252. India Drug Discovery, by End User USD Million (2023-2028)
  • Table 253. India Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 254. South Korea Drug Discovery, by Type USD Million (2023-2028)
  • Table 255. South Korea Drug Discovery, by Technology USD Million (2023-2028)
  • Table 256. South Korea Drug Discovery, by Stages USD Million (2023-2028)
  • Table 257. South Korea Drug Discovery, by End User USD Million (2023-2028)
  • Table 258. South Korea Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 259. Taiwan Drug Discovery, by Type USD Million (2023-2028)
  • Table 260. Taiwan Drug Discovery, by Technology USD Million (2023-2028)
  • Table 261. Taiwan Drug Discovery, by Stages USD Million (2023-2028)
  • Table 262. Taiwan Drug Discovery, by End User USD Million (2023-2028)
  • Table 263. Taiwan Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 264. Australia Drug Discovery, by Type USD Million (2023-2028)
  • Table 265. Australia Drug Discovery, by Technology USD Million (2023-2028)
  • Table 266. Australia Drug Discovery, by Stages USD Million (2023-2028)
  • Table 267. Australia Drug Discovery, by End User USD Million (2023-2028)
  • Table 268. Australia Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 269. Rest of Asia-Pacific Drug Discovery, by Type USD Million (2023-2028)
  • Table 270. Rest of Asia-Pacific Drug Discovery, by Technology USD Million (2023-2028)
  • Table 271. Rest of Asia-Pacific Drug Discovery, by Stages USD Million (2023-2028)
  • Table 272. Rest of Asia-Pacific Drug Discovery, by End User USD Million (2023-2028)
  • Table 273. Rest of Asia-Pacific Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 274. Europe Drug Discovery, by Country USD Million (2023-2028)
  • Table 275. Europe Drug Discovery, by Type USD Million (2023-2028)
  • Table 276. Europe Drug Discovery, by Technology USD Million (2023-2028)
  • Table 277. Europe Drug Discovery, by Stages USD Million (2023-2028)
  • Table 278. Europe Drug Discovery, by End User USD Million (2023-2028)
  • Table 279. Europe Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 280. Germany Drug Discovery, by Type USD Million (2023-2028)
  • Table 281. Germany Drug Discovery, by Technology USD Million (2023-2028)
  • Table 282. Germany Drug Discovery, by Stages USD Million (2023-2028)
  • Table 283. Germany Drug Discovery, by End User USD Million (2023-2028)
  • Table 284. Germany Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 285. France Drug Discovery, by Type USD Million (2023-2028)
  • Table 286. France Drug Discovery, by Technology USD Million (2023-2028)
  • Table 287. France Drug Discovery, by Stages USD Million (2023-2028)
  • Table 288. France Drug Discovery, by End User USD Million (2023-2028)
  • Table 289. France Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 290. Italy Drug Discovery, by Type USD Million (2023-2028)
  • Table 291. Italy Drug Discovery, by Technology USD Million (2023-2028)
  • Table 292. Italy Drug Discovery, by Stages USD Million (2023-2028)
  • Table 293. Italy Drug Discovery, by End User USD Million (2023-2028)
  • Table 294. Italy Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 295. United Kingdom Drug Discovery, by Type USD Million (2023-2028)
  • Table 296. United Kingdom Drug Discovery, by Technology USD Million (2023-2028)
  • Table 297. United Kingdom Drug Discovery, by Stages USD Million (2023-2028)
  • Table 298. United Kingdom Drug Discovery, by End User USD Million (2023-2028)
  • Table 299. United Kingdom Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 300. Netherlands Drug Discovery, by Type USD Million (2023-2028)
  • Table 301. Netherlands Drug Discovery, by Technology USD Million (2023-2028)
  • Table 302. Netherlands Drug Discovery, by Stages USD Million (2023-2028)
  • Table 303. Netherlands Drug Discovery, by End User USD Million (2023-2028)
  • Table 304. Netherlands Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 305. Rest of Europe Drug Discovery, by Type USD Million (2023-2028)
  • Table 306. Rest of Europe Drug Discovery, by Technology USD Million (2023-2028)
  • Table 307. Rest of Europe Drug Discovery, by Stages USD Million (2023-2028)
  • Table 308. Rest of Europe Drug Discovery, by End User USD Million (2023-2028)
  • Table 309. Rest of Europe Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 310. MEA Drug Discovery, by Country USD Million (2023-2028)
  • Table 311. MEA Drug Discovery, by Type USD Million (2023-2028)
  • Table 312. MEA Drug Discovery, by Technology USD Million (2023-2028)
  • Table 313. MEA Drug Discovery, by Stages USD Million (2023-2028)
  • Table 314. MEA Drug Discovery, by End User USD Million (2023-2028)
  • Table 315. MEA Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 316. Middle East Drug Discovery, by Type USD Million (2023-2028)
  • Table 317. Middle East Drug Discovery, by Technology USD Million (2023-2028)
  • Table 318. Middle East Drug Discovery, by Stages USD Million (2023-2028)
  • Table 319. Middle East Drug Discovery, by End User USD Million (2023-2028)
  • Table 320. Middle East Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 321. Africa Drug Discovery, by Type USD Million (2023-2028)
  • Table 322. Africa Drug Discovery, by Technology USD Million (2023-2028)
  • Table 323. Africa Drug Discovery, by Stages USD Million (2023-2028)
  • Table 324. Africa Drug Discovery, by End User USD Million (2023-2028)
  • Table 325. Africa Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 326. North America Drug Discovery, by Country USD Million (2023-2028)
  • Table 327. North America Drug Discovery, by Type USD Million (2023-2028)
  • Table 328. North America Drug Discovery, by Technology USD Million (2023-2028)
  • Table 329. North America Drug Discovery, by Stages USD Million (2023-2028)
  • Table 330. North America Drug Discovery, by End User USD Million (2023-2028)
  • Table 331. North America Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 332. United States Drug Discovery, by Type USD Million (2023-2028)
  • Table 333. United States Drug Discovery, by Technology USD Million (2023-2028)
  • Table 334. United States Drug Discovery, by Stages USD Million (2023-2028)
  • Table 335. United States Drug Discovery, by End User USD Million (2023-2028)
  • Table 336. United States Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 337. Canada Drug Discovery, by Type USD Million (2023-2028)
  • Table 338. Canada Drug Discovery, by Technology USD Million (2023-2028)
  • Table 339. Canada Drug Discovery, by Stages USD Million (2023-2028)
  • Table 340. Canada Drug Discovery, by End User USD Million (2023-2028)
  • Table 341. Canada Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 342. Mexico Drug Discovery, by Type USD Million (2023-2028)
  • Table 343. Mexico Drug Discovery, by Technology USD Million (2023-2028)
  • Table 344. Mexico Drug Discovery, by Stages USD Million (2023-2028)
  • Table 345. Mexico Drug Discovery, by End User USD Million (2023-2028)
  • Table 346. Mexico Drug Discovery, by Therapeutic Area USD Million (2023-2028)
  • Table 347. Drug Discovery: by Type(USD/Units)
  • Table 348. Research Programs/Design for This Report
  • Table 349. Key Data Information from Secondary Sources
  • Table 350. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug Discovery: by Type USD Million (2017-2022)
  • Figure 5. Global Drug Discovery: by Technology USD Million (2017-2022)
  • Figure 6. Global Drug Discovery: by Stages USD Million (2017-2022)
  • Figure 7. Global Drug Discovery: by End User USD Million (2017-2022)
  • Figure 8. Global Drug Discovery: by Therapeutic Area USD Million (2017-2022)
  • Figure 9. South America Drug Discovery Share (%), by Country
  • Figure 10. Asia Pacific Drug Discovery Share (%), by Country
  • Figure 11. Europe Drug Discovery Share (%), by Country
  • Figure 12. MEA Drug Discovery Share (%), by Country
  • Figure 13. North America Drug Discovery Share (%), by Country
  • Figure 14. Global Drug Discovery: by Type USD/Units (2017-2022)
  • Figure 15. Global Drug Discovery share by Players 2022 (%)
  • Figure 16. Global Drug Discovery share by Players (Top 3) 2022(%)
  • Figure 17. Global Drug Discovery share by Players (Top 5) 2022(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 21. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 25. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Agilent Technologies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Agilent Technologies Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 31. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 35. Caliper Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 36. Caliper Life Sciences (United States) Revenue: by Geography 2022
  • Figure 37. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 39. Shimadzu Corp. (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Shimadzu Corp. (Japan) Revenue: by Geography 2022
  • Figure 41. Evotec (Germany) Revenue, Net Income and Gross profit
  • Figure 42. Evotec (Germany) Revenue: by Geography 2022
  • Figure 43. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2022
  • Figure 45. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 46. Biogen (United States) Revenue: by Geography 2022
  • Figure 47. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 48. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 49. IQVIA Inc (United States) Revenue, Net Income and Gross profit
  • Figure 50. IQVIA Inc (United States) Revenue: by Geography 2022
  • Figure 51. Piramal Pharma Solutions (India) Revenue, Net Income and Gross profit
  • Figure 52. Piramal Pharma Solutions (India) Revenue: by Geography 2022
  • Figure 53. Domainex (united Kingdom) Revenue, Net Income and Gross profit
  • Figure 54. Domainex (united Kingdom) Revenue: by Geography 2022
  • Figure 55. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 56. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2022
  • Figure 57. Jubilant Pharmova Limited (India) Revenue, Net Income and Gross profit
  • Figure 58. Jubilant Pharmova Limited (India) Revenue: by Geography 2022
  • Figure 59. Viva Biotech (China) Revenue, Net Income and Gross profit
  • Figure 60. Viva Biotech (China) Revenue: by Geography 2022
  • Figure 61. Global Drug Discovery: by Type USD Million (2023-2028)
  • Figure 62. Global Drug Discovery: by Technology USD Million (2023-2028)
  • Figure 63. Global Drug Discovery: by Stages USD Million (2023-2028)
  • Figure 64. Global Drug Discovery: by End User USD Million (2023-2028)
  • Figure 65. Global Drug Discovery: by Therapeutic Area USD Million (2023-2028)
  • Figure 66. South America Drug Discovery Share (%), by Country
  • Figure 67. Asia Pacific Drug Discovery Share (%), by Country
  • Figure 68. Europe Drug Discovery Share (%), by Country
  • Figure 69. MEA Drug Discovery Share (%), by Country
  • Figure 70. North America Drug Discovery Share (%), by Country
  • Figure 71. Global Drug Discovery: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Abbott Laboratories (United States)
  • Merck & Co. Inc. (United States)
  • Agilent Technologies Inc. (United States)
  • Eli Lilly and Company (United States)
  • Roche Holding AG (Switzerland)
  • Bayer AG (Germany)
  • Caliper Life Sciences (United States)
  • AstraZeneca PLC (United Kingdom)
  • Shimadzu Corp. (Japan)
  • Evotec (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Biogen (United States)
  • Bristol-Myers Squibb Company (United States)
  • IQVIA Inc (United States)
  • Piramal Pharma Solutions (India)
  • Domainex (united Kingdom)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Jubilant Pharmova Limited (India)
  • Viva Biotech (China)
Additional players considered in the study are as follows:
Select User Access Type

Key Highlights of Report


Oct 2023 243 Pages 54 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drug Discovery Quantitative research analysis
Global Drug Discovery Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Drug Discovery study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Drug Discovery Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Drug Discovery market is expected to see growth rate of xx%.
The Drug Discovery market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Drug Discovery Report?

Have a Query? Click Here

Other Related Reports

Live Cell Encapsulation Comprehensive Study by Type (Alginate, HEMA-MMA (Hydroxyethyl Methacrylate-methyl Methacrylate), Siliceous Encapsulates, Cellulose Sulfate, PAN-PVC (Acrylonitrile Vinyl Chlori...
$ 3750
DNA 3D Printing Comprehensive Study by Type (3D Printer, Laser Technology, DNA Sample, Enzyme), Application (Bioengineering / R&D, Pharmaceutical Drugs/ Therapies, Agriculture Industry, Energy, Other...
$ 3650
HCS Software and Services Comprehensive Study by Type (HCS Services, HCS Software), Application (Compound Profiling, Primary and Secondary Screening, Automated Microscopy and Image Analysis, Target I...
$ 3750
Aerospace and Life Science TIC Comprehensive Study by Type (Testing Services, Inspection Services, Certification Services, Others), Application (Aerospace, Medical & Life Sciences), Sourcing (In-hous...
$ 3500
Life Science & Analytical Instruments Comprehensive Study by Application (Clinical Analysis., Forensic Analysis., Chemical, Food & Beverage Analysis., Pharmaceutical Analysis., Life science research,...
$ 3800
Chiral Chromatography Comprehensive Study by Type (Pre-Packed Columns, Empty Columns), Application (Pharmaceuticals, Agrochemicals, Flavors/Fragrances), Technology (Biological Separation, Asymmetric ...
$ 3500